Stock Events

Stock Events

Legend Biotech 

$21.97
58
+$0.22+1.01% 10:41 Today

Statistics

Day High
21.77
Day Low
21.76
52W High
37.5
52W Low
16.24
Volume
48,037
Avg. Volume
-
Mkt Cap
4.23B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

11AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.83
-0.57
-0.31
-0.05
Expected EPS
-0.21
Actual EPS
-0.34

Financials

-28.85%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.03BRevenue
-296.8MNet Income

Analyst Ratings

47.13Average Price Target
The highest estimate is 78.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LEGN. It's not an investment recommendation.
NVIDIA
15
NVDA
Microsoft
11
MSFT
Alphabet
11
GOOGL
Amazon
10
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, is a key player in the CAR-T therapy market, making it a direct competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis is a pioneer in CAR-T therapy with Kymriah, directly competing with Legend Biotech's CAR-T therapies.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, which competes with Legend Biotech's approach to cancer treatment.
Precigen
PGEN
Mkt Cap2.49B
Precigen's focus on gene and cell therapies, including CAR-T, makes it a competitor in the biotech space against Legend Biotech.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in gene editing, a technology that can be applied to CAR-T therapy development, positioning it as a competitor.

About

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Show more...
CEO
Alan S. Bash
Employees
3200
Country
Cayman Islands
ISIN
US52490G1022
WKN
000A2P5AH

Listings

STU
DE
9LB.STU
MU
DE
9LB.MU
XNAS
US
LEGN
F
DE
9LB.F

0 Comments

Share your thoughts

FAQ

What is Legend Biotech stock price today?▼
The current price of LEGN is $21.97 USD — it has increased by +1.01% in the past 24 hours. Watch Legend Biotech stock price performance more closely on the chart.
What is Legend Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Legend Biotech stocks are traded under the ticker LEGN.
Is Legend Biotech stock price growing?▼
LEGN stock has risen by +9.41% compared to the previous week, the month change is a +13.7% rise, over the last year Legend Biotech has showed a -37.84% decrease.
What is Legend Biotech market cap?▼
Today Legend Biotech has the market capitalization of 4.23B
What were Legend Biotech earnings last quarter?▼
LEGN earnings for the last quarter are -0.34 USD per share, whereas the estimation was -0.21 USD resulting in a -61.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Legend Biotech revenue for the last year?▼
Legend Biotech revenue for the last year amounts to 1.03B USD.
What is Legend Biotech net income for the last year?▼
LEGN net income for the last year is -296.8M USD.
How many employees does Legend Biotech have?▼
As of September 04, 2026, the company has 3,200 employees.
In which sector is Legend Biotech located?▼
Legend Biotech operates in the Health & Wellness sector.
When did Legend Biotech complete a stock split?▼
Legend Biotech has not had any recent stock splits.
Where is Legend Biotech headquartered?▼
Legend Biotech is headquartered in Somerset, Cayman Islands.